Associate Scientific Directors -
Dr. Jonathan Licht & Dr. Ethan Dmitrovsky
Dr. Jonathan Licht
Jonathan D. Licht, MD, is the Associate Director for Clinical Sciences and
Chief, Hematology/Oncology at Northwestern University's Feinberg School of
Medicine. Dr. Licht's area of research is the molecular understanding of the
blocks in differentiation causing leukemia.
Prior to joining the Cancer Center, Dr. Licht was the Chief of the Division
of Hematology/Oncology at the Mount. Sinai School of Medicine in New York.
He is a graduate of Columbia University College of Physicians and Surgeons
and was a resident at Beth Israel Hospital, Harvard Medical School. He did
his fellowship training in Medical Oncology at the Dana Farber Cancer
Institute.
Understanding aberrant transcriptional repression as a cause of
hematological malignancy, including acute promyelocytic leukemia and large
cell lymphoma is the broad goal of Dr. Licht's research program, and he is
utilizing small molecules and peptide interference strategies to reverse
this repression. He also studies kidney development and signal transduction
as an outgrowth of studies of the WT1 tumor suppressor.
Dr. Licht was a recipient of a Leukemia Society Scholar Award and currently
holds a Burroughs-Wellcome Clinical Scientist Award in Translational
Research. He is a Councilor of the American Society of Clinical
Investigation and a member of the Association of American Physicians. Dr.
Licht is a charter member of the NIH Cancer Molecular Pathology Study
section and has served on American Cancer Society and Leukemia and Lymphoma
Society review panels.
Dr. Ethan Dmitrovsky
Dr. Ethan Dmitrovsky is the Andrew G. Wallace Professor at Dartmouth Medical School and an American Cancer Society Clinical Research Professor. He serves as the Senior Advisor to the President of Dartmouth College for science and technology, on advisory committees of the Lance Armstrong Foundation and as a member of the Board of Scientific Counselors of the National Cancer Institute.
His research program studies the use of natural and synthetic vitamin A derivatives, the retinoids, in cancer therapy and chemoprevention. He and his colleagues reported on the use of retinoids in differentiation therapy for acute promyelocytic leukemia and developed a diagnostic molecular test for this leukemia. His team also uncovered a mechanism whereby retinoids degrade cyclins through the proteasome. This is a new target for cancer therapy and chemoprevention, as has been confirmed in his team's recent clinical trials.
He is a graduate of Harvard College and Cornell University Medical College and was an intern/resident at New York Hospital/Memorial Sloan-Kettering Cancer Center in New York. He completed training in medical oncology at the National Cancer Institute. Before joining Dartmouth, he was a faculty member at Memorial Sloan-Kettering Cancer Center.
|
